Table 3.
Performances of contrast-enhanced computed tomography, positron emission tomography/computed tomography, and positron emission tomography/contrast-enhanced computed tomography fusion images in the stage assessments of pancreatic cancer n (%)
|
Peripancreatic vessel invasion |
Regional lymph node metastasis |
Distant metastasis |
|||||||||||||
| SEN | SPE | PPV | NPV | ACC | SEN | SPE | PPV | NPV | ACC | SEN | SPE | PPV | NPV | ACC | |
| CECT | 14 (93.3) | 15 (93.8) | 14 (93.3) | 15 (93.8) | 29 (93.5) | 12 (63.2) | 11 (91.7) | 12 (92.3) | 11 (61.1) | 23 (74.2) | 10 (58.8) | 33 (100) | 10 (100) | 33 (82.5) | 43 (86.0) |
| Routine PET/CT | 4 (26.7) | 12 (75.0) | 4 (50) | 12 (52.2) | 16 (51.6) | 15 (78.9) | 10 (83.3) | 15 (88.2) | 10 (71.4) | 25 (80.6) | 14 (82.4) | 30 (90.9) | 14 (82.4) | 30 (90.9) | 44 (88) |
| PET/CECT | 14 (93.3) | 15 (93.8) | 14 (93.3) | 15 (93.8) | 29 (93.5) | 17 (89.5) | 11 (91.7) | 17 (94.4) | 11 (84.6) | 28 (90.3) | 16 (94.1) | 32 (97.0) | 16 (94.1) | 32 (97.0) | 48 (96.0) |
| PET/CECT vs PET/CT | χ2 = 13.889 P = 0.001 | χ2 = 2.133 P = 0.144 | χ2 = 5.759 P = 0.016 | χ2 = 7.657 P = 0.006 | χ2 = 13.697 P = 0.001 | χ2 = 0.792 P = 0.374 | χ2 = 0.381 P = 0.537 | χ2 = 0.430 P = 0.512 | χ2 = 0.678 P = 0.410 | χ2 = 1.170 P = 0.279 | χ2 = 1.133 P = 0.287 | χ2 = 1.065 P = 0.302 | χ2 = 1.133 P = 0.287 | χ2 = 1.065 P = 0.302 | χ2 = 2.174 P = 0.140 |
| PET/CECT vs CECT | χ2 = 0.000 P = 1.000 | χ2 = 0.000 P = 1.000 | χ2 = 0.000 P = 1.000 | χ2 = 0.000 P = 1.000 | χ2 = 0.000 P = 1.000 | χ2 = 3.640 P = 0.056 | χ2 = 0.000 P = 1.000 | χ2 = 0.057 P = 0.811 | χ2 = 2.024 P = 0.155 | χ2 = 2.763 P = 0.096 | χ2 = 5.885 P = 0.015 | χ2 = 1.015 P = 0.314 | χ2 = 0.611 P = 0.434 | χ2 = 3.880 P = 0.049 | χ2 = 3.053 P = 0.081 |
PET/CT: Positron emission tomography/computed tomography; CECT: Contrast-enhanced CT; SEN: Sensibility; SPE: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; ACC: Accuracy.